患有血清NMDA受体自身抗体的癌症患者的记忆缺陷
Frederik Bartels1,2,3,4, Andreea Tapuc3,5, Kristin Rentzsch6
1Department of Neurology, Charité - Universitätsmedizin Berlin, Germany.
Neurology
|December 26, 2025
概括
血清N-甲基-D-酸盐受体 (NMDAR) 自体抗体与癌症患者的记忆缺陷有关. 这些发现表明,NMDAR自身抗体可能是癌症相关认知障碍的生物标志物.
科学领域:
- 神经免疫学 神经免疫学
- 在瘤学瘤学.
- 认知神经科学 认知神经科学
背景情况:
- 神经元自身抗体,特别是IgA/IgM N-甲基-D-酸盐受体 (NMDAR) 自体,在癌症患者中很常见.
- 这些自身抗体对癌症认知功能的临床意义尚不清楚.
研究的目的:
- 评估癌症患者具有血清NMDAR自身抗体的认知功能.
- 为了比较自身抗体阳性和自身抗体阴性癌症患者之间的认知表现.
主要方法:
- 跨截面病例控制研究,涉及德国1,055名癌症患者.
- 认知评估包括口头记忆,视觉空间记忆和工作记忆,在对抗体状态盲目进行.
- 排除了对认知功能障碍产生混因素的患者.
主要成果:
- 与匹配的对照组相比,IgA/IgM NMDAR自身抗体的56名患者表现出口记忆,视觉空间记忆和工作记忆的显著损伤.
- 记忆功能下降与IgA NMDAR自身抗体水平的增加相关.
- 两组之间没有观察到注意力,执行功能或口语流性的显著差异.
结论:
- 血清NMDAR自身抗体与癌症患者的孤立记忆缺陷有关.
- 这些自身抗体可能作为一种潜在的生物标志物,用于识别与癌症相关的认知障碍.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
503
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Amnesia
407
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
407


